You are here: Industry Insights > Sandoz

News List

Amgen wins court patent ruling over Sandoz biosimilar europeanpharmaceuticalreview
August 14, 2019
The US District Court has decided in favour of Amgen’s Enbrel, ruling over Sandoz’s Erelzi in a patent conflict.
With Enbrel patent victory, Amgen scores major win against biosims—and Sandoz takes a big loss fiercepharma
August 13, 2019
Enbrel, its top-selling product, has steered clear of a major stumbling block, thanks to a victory in patent court that kicks potential biosimilars years down the road.
Enbrel and Its Patent Layout: The Period of Market Exclusivity until 2029! PharmaSources/zhixing
July 30, 2019
Patents are fortresses of new drugs. The patent layout of Enbrel is quite impressive: the span from the first application in 1995 to the patent expiration in 2029 reaches 34 years.
Sandoz launches oncology generic gefitinib in 13 EU countries biospectrumasia
July 13, 2019
Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK
Sandoz launches epinephrine injection amid shortage in US pharmaceutical-technology
July 12, 2019
Novartis unit Sandoz has launched an epinephrine injection product at local pharmacies in the US, as a shortage of the treatment continues across the country.
Sandoz receives regulatory approval from NMPA for Rosuvastatin biospectrumasia
May 12, 2019
Sandoz is the first multinational pharmaceutical company to receive such an approval under the recently introduced QCE system
Sandoz signs cancer drug deal with EirGenix pharmaceutical-technology
May 05, 2019
Sandoz has signed an agreement with EirGenix for the commercialisation of a trastuzumab biosimilar.
Novartis brings in GlaxoSmithKline's Richard Saynor to lead turnaround of Sandoz unit firstwordpharma
April 25, 2019
Novartis announced Wednesday alongside its first-quarter financial results, that Richard Saynor, the current senior vice president of classic and established products, commercial and digital platforms at GlaxoSmithKline.
Sandoz resubmits BLA for biosimilar pegfilgrastim to FDA pharmaceutical-technology
April 23, 2019
Sandoz resubmits BLA for biosimilar pegfilgrastim to FDA
Sandoz to commercialise Shionogi’s Rizmoic in European markets pharmaceutical-technology
April 23, 2019
Sandoz to commercialise Shionogi’s Rizmoic in European markets...

Previous page 1 2 3 4 5 6 7 8 Next page